Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi
Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.
You may also be interested in...
Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.
Roche To Reinvest Savings Into R&D And Keep Prices Low
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.